Quantitative J-resolved prostate spectroscopy using two-dimensional prior-knowledge fitting

Magnetic Resonance in Medicine

Volumn 59, Issue 5, 2008, Pages 966-972

  Lange, Thomas ^a   Schulte, Rolf F ^a,b   Boesiger, Peter ^a  

^a ETH ZURICH   (Switzerland)

^b GE GLOBAL RESEARCH   (Germany)

Author keywords

JPRESS; Metabolite quantification; MRS; Prostate; Two dimensional fitting

Indexed keywords

BIOMOLECULES; DISEASES; POLYOLS; PROFITABILITY; UROLOGY;

INFORMATION CONTENTS; JPRESS; LINEAR COMBINATIONS; METABOLITE CONCENTRATIONS; PEAK INTEGRATION; PROSTATE; PROSTATE CANCERS; TWO DIMENSIONAL (2 D);

METABOLITES;

CHOLINE; CITRIC ACID; CREATINE; INOSITOL; SCYLLO INOSITOL; SPERMINE;

ADULT; ARTICLE; CANCER DIAGNOSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INFORMATION PROCESSING; INTERMETHOD COMPARISON; J RESOLVED PROSTATE SPECTROSCOPY; MALE; MATHEMATICAL ANALYSIS; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SPECTROSCOPY; STATISTICAL ANALYSIS; TWO DIMENSIONAL PRIOR KNOWLEDGE FITTING; VALIDATION PROCESS;

EID: 42549157594     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21438     Document Type: Article

References (34)

1. 1 Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002 ; 16: 451–463.
2. 2 Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: Localization with three‐dimensional proton MR spectroscopic imaging—clinicopathologic study. Radiology 1999 ; 213: 473–480.
3. 3 Cheng LL, Wu CL, Smith MR, Gonzalez RG. Non‐destructive quantitation of spermine in human prostate tissue samples using HRMAS H‐1 NMR spectroscopy at 9.4 T. FEBS Lett 2001 ; 494: 112–116.
4. 4 Garcia‐Segura JM, Sanchez‐Chapado M, Ibarburen C, Viano J, Angulo JC, Gonzalez J, Rodriguez‐Vallejo JM. In vivo proton magnetic resonance spectroscopy of diseased prostate: Spectroscopic features of malignant versus benign pathology. Magn Reson Imaging 1999 ; 17: 755–765.
5. 5 Lynch MJ, Nicholson JK. Proton MRS of human prostatic fluid: Correlations between citrate, spermine, and myo‐inositol levels and changes with disease. Prostate 1997 ; 30: 248–255.
6. 6 Swanson MG, Vigneron DB, Tran TKC, Sailasuta N, Hurd RE, Kurhanewicz J. Single‐voxel oversampled J‐resolved spectroscopy of in vivo human prostate tissue. Magn Reson Med 2001 ; 45: 973–980.
7. 7 van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 2000 ; 10: 153–159.
8. 8 Kurhanewicz J, Dahiya R, Macdonald JM, Chang LH, James TL, Narayan P. Citrate alterations in primary and metastatic human prostatic adenocarcinomas ‐ H‐1 magnetic‐resonance spectroscopy and biochemical‐study. Magn Reson Med 1993 ; 29: 149–157.
9. 9 Kumar A, Ernst RR. Influence of nonresonant nuclei on NMR spin echoes in liquids and in solids. J Magn Reson 1976 ; 24: 425–447.
10. 10 Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three‐dimensional H‐1 MR spectroscopic imaging of the in situ human prostate with high (0.24‐0.1‐cm(3)) spatial resolution. Radiology 1996 ; 198: 795–805.
11. 11 Males RG, Vigneron DB, Star‐Lack O, Falbo SC, Nelson SJ, Hricak H, Kurhanewicz J. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D H‐1 magnetic resonance spectroscopic imaging. Magn Reson Med 2000 ; 43: 17–22.
12. 12 van Dorsten FA, van der Graaf M, Engelbrecht MRW, van Leenders G, Verhofstad A, Rijpkema M, de la Rosette J, Barentsz JO, Heerschap A. Combined quantitative dynamic contrast‐enhanced MR imaging and H‐1 MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004 ; 20: 279–287.
13. 13 Pels P, Ozturk‐Isik E, Swanson MG, Vanhamme L, Kurhanewicz J, Nelson SJ, Van Huffel S. Quantification of prostate MRSI data by model‐based time domain fitting and frequency domain analysis. NMR Biomed 2006 ; 19: 188–197.
14. 14 Scheenen TWJ, Klomp DWJ, Roll SA, Futterer JJ, Barentsz JO, Heerschap A. Fast acquisition‐weighted three‐dimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med 2004 ; 52: 80–88.
15. 15 Nelson SJ, Brown TR. A method for automatic quantification of one‐dimensional spectra with low signal‐to‐noise ratio. J Magn Reson 1987 ; 75: 229–243.
16. 16 Schiebler ML, Miyamoto KK, White M, Maygarden SJ, Mohler JL. Invitro high‐resolution H‐1‐spectroscopy of the human prostate ‐ benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magn Reson Med 1993 ; 29: 285–291.
17. 17 Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J. Quantitative analysis of prostate metabolites using H‐1 HR‐MAS spectroscopy. Magn Reson Med 2006 ; 55: 1257–1264.
18. 18 Fowler AH, Pappas AA, Holder JC, Finkbeiner AE, Dalrymple GV, Mullins MS, Sprigg JR, Komoroski RA. Differentiation of human prostate‐cancer from benign hypertrophy by in vitro H‐1‐NMR. Magn Reson Med 1992 ; 25: 140–147.
19. 19 Yue K, Marumoto A, Binesh N, Thomas MA. 2D JPRESS of human prostates using an endorectal receiver coil. Magn Reson Med 2002 ; 47: 1059–1064.
20. 20 Kim DH, Margolis D, Xing L, Daniel B, Spielman D. In vivo prostate magnetic resonance spectroscopic imaging using two‐dimensional J‐resolved PRESS at 3 T. Magn Reson Med 2005 ; 53: 1177–1182.
21. 21 Lange T, Trabesinger AH, Schulte RF, Dydak U, Boesiger P. Prostate spectroscopy at 3 Tesla using two‐dimensional S‐PRESS. Magn Reson Med 2006 ; 56: 1220–1228.
22. 22 De Beer R, Vanormondt D, Pijnappel WWF. Quantification of 1‐D and 2‐D magnetic‐resonance time domain signals. Pure Appl Chem 1992 ; 64: 815–823.
23. 23 Slotboom J, Boesch C, Kreis R. Versatile frequency domain fitting using time domain models and prior knowledge. Magn Reson Med 1998 ; 39: 899–911.
24. 24 Schulte RF, Boesiger P. ProFit: two‐dimensional prior‐knowledge fitting of J‐resolved spectra. NMR Biomed 2006 ; 19: 255–263.
25. 25 Provencher SW. Estimation of metabolite concentrations from localized in‐vivo proton NMR‐spectra. Magn Reson Med 1993 ; 30: 672–679.
26. 26 Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron‐Demilly D. Cramer‐Rao bounds: an evaluation tool for quantitation. NMR Biomed 2001 ; 14: 278–283.
27. 27 Schulte RF, Lange T, Beck J, Meier D, Boesiger P. Improved two‐dimensional J‐resolved spectroscopy. NMR Biomed 2006 ; 19: 264–270.
28. 28 Smith SA, Levante TO, Meier BH, Ernst RR. Computer‐simulations in magnetic‐resonance—an object‐oriented programming approach. J Magn Reson A 1994 ; 106: 75–105.
29. 29 Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000 ; 13: 129–153.
30. 30 Willker W, Flogel U, Leibfritz D. A H‐1/C‐13 inverse 2D method for the analysis of the polyamines putrescine, spermidine and spermine in cell extracts and biofluids. NMR Biomed 1998 ; 11: 47–54.
31. 31 Heerschap A, Jager GJ, vanderGraaf M, Barentsz JO, Ruijs SHJ. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin‐echo pulse sequence. Magn Reson Med 1997 ; 37: 204–213.
32. 32 Kumar R, Kumar M, Jagannathan NR, Gupta NP, Hemal AK. Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate. Urol Res 2004 ; 32: 36–40.
33. 33 Liney GP, Turnbull LW, Knowles AJ. In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland. NMR Biomed 1999 ; 12: 39–44.
34. 34 Liney GP, Turnbull LW, Lowry M, Turnbull LS, Knowles AJ, Horsman A. In vivo quantification of citrate concentration and water T‐2 relaxation time of the pathologic prostate gland using H‐1 MRS and MRI. Magn Reson Imaging 1997 ; 15: 1177–1186.